- Home
- AIRS vs NBTX Comparison
AIRS vs NBTX Comparison
Compare AIRS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- NBTX
- Stock Information
- Founded
- AIRS 2012
- NBTX 2003
- Country
- AIRS United States
- NBTX France
- Employees
- AIRS N/A
- NBTX N/A
- Industry
- AIRS Medical/Nursing Services
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- NBTX Health Care
- Exchange
- AIRS Nasdaq
- NBTX Nasdaq
- Market Cap
- AIRS 166.3M
- NBTX 167.8M
- IPO Year
- AIRS 2021
- NBTX 2020
- Fundamental
- Price
- AIRS $4.63
- NBTX $4.17
- Analyst Decision
- AIRS Hold
- NBTX Strong Buy
- Analyst Count
- AIRS 3
- NBTX 1
- Target Price
- AIRS $3.75
- NBTX $8.00
- AVG Volume (30 Days)
- AIRS 558.2K
- NBTX 11.2K
- Earning Date
- AIRS 05-02-2025
- NBTX 04-02-2025
- Dividend Yield
- AIRS N/A
- NBTX N/A
- EPS Growth
- AIRS N/A
- NBTX N/A
- EPS
- AIRS N/A
- NBTX N/A
- Revenue
- AIRS $172,101,000.00
- NBTX N/A
- Revenue This Year
- AIRS N/A
- NBTX N/A
- Revenue Next Year
- AIRS $5.46
- NBTX $221.06
- P/E Ratio
- AIRS N/A
- NBTX N/A
- Revenue Growth
- AIRS N/A
- NBTX N/A
- 52 Week Low
- AIRS $1.53
- NBTX $2.76
- 52 Week High
- AIRS $9.20
- NBTX $7.29
- Technical
- Relative Strength Index (RSI)
- AIRS 77.74
- NBTX 66.44
- Support Level
- AIRS $4.16
- NBTX $4.06
- Resistance Level
- AIRS $4.57
- NBTX $4.20
- Average True Range (ATR)
- AIRS 0.39
- NBTX 0.13
- MACD
- AIRS 0.06
- NBTX 0.04
- Stochastic Oscillator
- AIRS 88.34
- NBTX 95.64
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.